La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

CytomX Therapeutics Croissance future

Future contrôle des critères 0/6

Les revenus et les bénéfices de CytomX Therapeutics devraient diminuer respectivement de 15.2% et de 27.2% par an, tandis que le BPA devrait croître de diminuer de 26.1% par an.

Informations clés

-27.2%

Taux de croissance des bénéfices

-26.1%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.3%
Taux de croissance des recettes	-15.2%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Good
Dernière mise à jour	09 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

May 02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 29

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Feb 13

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10

CytomX Therapeutics to cut workforce by about 40%

Jul 13

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Jul 06

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08

Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being

Jun 10

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:CTMX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	67	-57	-37	N/A	2
12/31/2025	73	-54	-40	-66	5
12/31/2024	100	-33	-44	-65	6
6/30/2024	120	11	-86	-86	N/A
3/31/2024	119	17	-92	-91	N/A
12/31/2023	101	-1	-57	-56	N/A
9/30/2023	95	-10	-36	-35	N/A
6/30/2023	79	-42	-52	-51	N/A
3/31/2023	68	-71	-61	-60	N/A
12/31/2022	53	-99	-113	-111	N/A
9/30/2022	21	-149	-142	-141	N/A
6/30/2022	27	-143	-138	-136	N/A
3/31/2022	30	-132	-132	-130	N/A
12/31/2021	37	-116	-121	-119	N/A
9/30/2021	66	-72	-107	-105	N/A
6/30/2021	66	-64	-103	-100	N/A
3/31/2021	67	-61	23	25	N/A
12/31/2020	68	-65	3	5	N/A
9/30/2020	92	-54	-9	-7	N/A
6/30/2020	85	-63	-8	-5	N/A
3/31/2020	78	-76	-154	-151	N/A
12/31/2019	27	-133	-144	-140	N/A
9/30/2019	61	-99	-144	-140	N/A
6/30/2019	62	-99	-126	-122	N/A
3/31/2019	75	-83	-105	-100	N/A
12/31/2018	60	-85	-79	-76	N/A
9/30/2018	75	-52	-28	-25	N/A
6/30/2018	87	-39	-27	-25	N/A
3/31/2018	74	-50	N/A	175	N/A
12/31/2017	72	-43	N/A	170	N/A
9/30/2017	51	-58	N/A	150	N/A
6/30/2017	30	-62	N/A	142	N/A
3/31/2017	24	-51	N/A	-16	N/A
12/31/2016	15	-59	N/A	-2	N/A
9/30/2016	11	-57	N/A	-12	N/A
6/30/2016	9	-57	N/A	-6	N/A
3/31/2016	8	-50	N/A	-28	N/A
12/31/2015	8	-42	N/A	-27	N/A
9/30/2015	8	-36	N/A	-24	N/A
6/30/2015	8	-26	N/A	30	N/A
3/31/2015	6	-24	N/A	31	N/A
12/31/2014	5	-35	N/A	32	N/A
12/31/2013	1	-19	N/A	-8	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Les bénéfices de CTMX devraient diminuer au cours des 3 prochaines années ( -27.2% par an).

Bénéfices vs marché: Les bénéfices de CTMX devraient diminuer au cours des 3 prochaines années ( -27.2% par an).

Croissance élevée des bénéfices: Les bénéfices de CTMX devraient baisser au cours des trois prochaines années.

Chiffre d'affaires vs marché: Les revenus de CTMX devraient diminuer au cours des 3 prochaines années ( -15.2% par an).

Croissance élevée des revenus: Les revenus de CTMX devraient diminuer au cours des 3 prochaines années ( -15.2% par an).

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CTMX devrait être élevé dans 3 ans

CytomX Therapeutics Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 138%

Consensus EPS estimates fall by 35%

Consensus EPS estimates fall by 29%

Price target increased by 47% to US$4.00

Consensus estimates of losses per share improve by 43%

Consensus revenue estimates increase by 12%, EPS downgraded

Recent updates

Consensus EPS estimates fall by 138%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 16%

New minor risk - Market cap size

CytomX Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 35%

Investor sentiment deteriorates as stock falls 53%

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

Consensus EPS estimates fall by 29%

Price target increased by 47% to US$4.00

CytomX Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors

CytomX Therapeutics, Inc., Annual General Meeting, May 15, 2024

Chairman & CEO exercised options to buy US$239k worth of stock.

Consensus estimates of losses per share improve by 43%

CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors

Consensus revenue estimates increase by 12%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Price target increased by 9.6% to US$2.73

New minor risk - Market cap size

CytomX Therapeutics, Inc. Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

New minor risk - Profitability

Forecast breakeven date pushed back to 2024

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Consensus EPS estimates fall by 72%

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2023

CytomX Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CytomX Therapeutics, Inc. Presents Preclinical Profile of EpCAM-Directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

New minor risk - Market cap size

CytomX Therapeutics, Inc. announced that it has received $30 million in funding

Consensus revenue estimates increase by 18%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CytomX Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

CytomX Therapeutics, Inc. Appoints Yu-Waye Chu as Chief Medical Officer

New minor risk - Market cap size

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$0.66 loss

Full year 2022 earnings: EPS and revenues miss analyst expectations

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Price target decreased to US$3.31

High number of new and inexperienced directors

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

CytomX Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CytomX Therapeutics, Inc. Announces Executive Changes

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

CytomX Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Cytomx Therapeutics, Inc. to Terminate Carlos Campoy as Chief Financial Officer, Effective as of September 30, 2022

CytomX Therapeutics to cut workforce by about 40%

CytomX Therapeutics, Inc. Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Price target decreased to US$10.75

CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors